PSA Levels May Measure Treatment Efficacy
Posted on: Tuesday, 18 April 2006, 18:00 CDT
Columbia University Medical Center scientists say certain changes in PSA levels may serve as surrogate endpoints for prostate cancer survival.
The researchers at New York-Presbyterian Hospital, members of the Southwest Oncology Group, are trying to speed the process of clinical trials and say the PSA biomarkers might be used to measure treatment efficacy.
Currently, the U.S. Food and Drug Administration accepts only survival as an endpoint of measure.
Dr. Daniel Petrylak, an associate professor, led researchers in analyzing the records of 551 men with prostate cancer. The scientists found there were several different changes in PSA levels, which could possibly serve as surrogate endpoints for survival.
The study is a follow-up to a landmark phase III trial published in the New England Journal of Medicine last year that found men with androgen-independent (hormone-refractory) metastatic prostate cancer who were treated with the chemotherapy drug Taxotere (docetaxel) Injection Concentrate in combination with the drug estramustine survived 20 percent longer than similar patients receiving the standard therapy.
Prostate cancer is the second leading cause of cancer death in men. About 30,350 men will die of the disease this year alone.
Source: United Press International
Related Articles
- Hall of Fame Quarterback Takes Hit From Prostate Cancer, Urges Men to be Proactive About Their Own Prostate Health
- Drug drops PSA in men with prostate cancer
- Black gay, bisexual men get less PSA tests
- Kidneys And Genito-Urinary System - Benign Prostatic Hyperplasia Drug Pipeline Report Provides Detail On The Top 20 Companies With Products In The Early And Late Stage Of Development
- Use of Sequenom's MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
- Genetic Mutation Increases the Risk of Cancer in Men
- Studies: Aspirin Cuts Cancer in Men, Not Women
- Research and Markets: Clinical Trials Have Shown the Lack of Activity of Estramustine in Hormone Refractory Prostate Cancer, But the Drug Is Still Commonly Used Because of the Lack of Alternatives
- Dendreon's Provenge is the First Vaccine Therapy for Prostate Cancer Shown to Extend Survival
- Powell Has Cancerous Prostate Removed
 |
 |
User Comments (0)
RSS Feeds